Understand the source comparison
Peptide Insurance Coverage 2026: Covered vs Excluded Compounds
Semaglutide (Ozempic, Wegovy) FDA-approved for T2DM and obesity Covered on most formularies Yes. Requires BMI >30 or >27 with comorbidities, failed lifestyle intervention $900–1,200/month retail; $300–500/month compounded Most accessible GLP-1 option with high
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Ozempic, Wegovy)
- FDA-approved for T2DM and obesity
- Covered on most formularies
- Yes. Requires BMI >30 or >27 with comorbidities, failed lifestyle intervention
- $900–1,200/month retail; $300–500/month compounded
- Most accessible GLP-1 option with highest approval rate when documentation complete
- Tirzepatide (Mounjaro, Zepbound)
- Covered on 70% of commercial formularies
- Yes. Similar to semaglutide criteria
- $1,000–1,400/month retail; $400–650/month compounded
- Dual GIP/GLP-1 mechanism shows superior weight loss vs semaglutide but narrower formulary presence
- Liraglutide (Victoza, Saxenda)
- Covered but often second-line to semaglutide
- Yes
- $1,100–1,300/month retail
- Daily injection requirement makes it less favorable despite similar efficacy
- BPC-157
- No FDA approval. Research use only
- Never covered
- N/A. Auto-denial
- $60–120/month research-grade
- Extensive preclinical data on tissue repair but zero insurance pathway
- Thymalin
- $80–150/month research-grade
- Immune modulation mechanism remains investigational; no formulary consideration
- Selank / Semax
- $70–140/month research-grade
- Anxiolytic and nootropic effects documented in Russian trials; US insurers don't recognize non-FDA approvals